Skip to main content

Table 3 Efficacy results of candidate vaccines for passive immunization against respiratory syncytial virus

From: An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Class Vaccine structure Clinical trial phase Results
Human polyclonal    
[77, 78] RSV IVIG Passed clinical trials - 40.7% relative reduction in hospitalization compared to placebo
- 63.4% relative reduction in hospitalization compared to placebo
Humanized monoclonal Ig[36] Palivizumab Passed clinical trials - 54.7% relative reduction in hospitalisation compared to placebo
Humanized monoclonal Ig[37] Motavizumab III - 50% relative reduction in medically attended LRI compared to Palivizumab.
- 26% relative reduction in hospitalisation compared to Palivizumab.